← Human Trials & Peer-Reviewed Studies
Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1)
Plain-language guide to PMID 11687463 (2001): double-blind and placebo-controlled controlled clinical trial study of Glatiramer Acetate, multiple sclerosis.
Key Facts
- PMID
- 11687463
- Journal
- Clinical and diagnostic laboratory immunology
- Year
- 2001
- Study type
- Controlled Clinical Trial
- Authors
- Balabanov R et al. (5 authors)
- DOI
- 10.1128/CDLI.8.6.1196-1203.2001
What This Study Did, in Plain Language
What Was Tested
Researchers studied Glatiramer Acetate in the context of multiple sclerosis in this controlled clinical trial publication.
In the present study, the researchers examined the expression of uPAR on monocytes in patients with relapsing-remitting multiple sclerosis (RRMS) not currently participating in a clinical trial and in patients with RRMS who were enrolled in a double-blind multicenter clinical trial designed to examine the effect of glatiramer acetate (copolymer 1; Copaxone) on relapsing disease.
Why It Was Studied
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system in which peripheral blood monocytes play an important role.
Patients with CPMS have sustained high levels of circulating uPAR-positive (uPAR(+)) monocytes.
Who Took Part
PubMed tags the participants as both men and women.
How the Study Was Run
The researchers set it up as a double-blind, placebo-controlled and multicenter study.
As a double-blind Glatiramer Acetate study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Glatiramer Acetate group a baseline to be compared against.
Running at several centres spread the Glatiramer Acetate study over different clinics and patient groups.
What Was Measured
Patients with CPMS have sustained high levels of circulating uPAR-positive (uPAR(+)) monocytes.
In comparison, patients with RRMS displayed variable levels of circulating uPAR(+) monocytes.
PubMed files the paper under topics including Antibodies, Monoclonal, Disability Evaluation, Flow Cytometry, Glatiramer Acetate, Immunosuppressive Agents, Longitudinal Studies and Monocytes.
What This Means in Plain Language
The paper is a double-blind, placebo-controlled and multicenter study of Glatiramer Acetate in people with multiple sclerosis.
The publication is from 2001 (Clinical and diagnostic laboratory immunology), a journal based in United States.
More context: the Glatiramer Acetate compound page, Multiple sclerosis research.
Our Notes on the Compound
Glatiramer Acetate: A mix of synthetic amino-acid chains (Copaxone) used in relapsing multiple sclerosis.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.